500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PTC Therapeutics Acquires Assets from Sangamo for $111 Million
To Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
Earnings Release
PTC Therapeutics Completes $550 Million Convertible Notes Offering
Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
Director Resignation - Alethia Young Steps Down from Board
Annual Meeting Results - Four Directors Elected at PTC Therapeutics
Q2
Q1
FY 2024
Q3
FY 2023
Notice of Exempt Offering of Securities
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence